PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Gut microbes (species: Bifidobacterium pseudolongum) increase Anti- CTLA4's activity.
Anti- CTLA4 (PubChem CID: 123)
Bifidobacterium pseudolongum (Tax ID: 1694)
increase activity
Immune checkpoint inhibitors (ICI) are an effective treatment in many types of cancer that enhance cytotoxic T cells killing activities against cancer cells. Inosine, a metabolite, secreted by the presence of Bifidobacterium pseudolongum in the intestine. ICI increases intestine permeability to inosine which augments its action as it has the ability to activate T cells through adenosine A2a receptors. therefore, the presence of Bifidobacterium pseudolongum can enhance ICI activity.

Browse Drug-Microbiome Relationship